m6A modification-mediated lncRNA TP53TG1 inhibits gastric cancer progression by regulating CIP2A stability

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Long noncoding RNAs (lncRNAs) are implicated in cancer, but their specific roles in tumor progression are often unknown.
• Gastric cancer (GC) remains a significant health concern with a need for novel therapeutic targets.

Purpose of the Study:

• To investigate the role of the lncRNA TP53TG1 in gastric cancer.
• To elucidate the molecular mechanisms underlying TP53TG1's function in GC progression.

Main Methods:

• Quantitative analysis of TP53TG1 expression in GC tissues and cell lines.
• Functional assays to assess the impact of TP53TG1 on GC cell proliferation, migration, invasion, cell cycle, and apoptosis.
• Investigation of the regulatory role of ALKBH5 on TP53TG1 stability and expression.
• Analysis of TP53TG1 interaction with CIP2A and its effect on the PI3K/AKT pathway.

Main Results:

• TP53TG1 expression was significantly downregulated in GC tissues and correlated with poor patient survival.
• Overexpression of TP53TG1 suppressed GC cell proliferation, metastasis, and cell cycle progression, while promoting apoptosis.
• ALKBH5 was found to destabilize TP53TG1, leading to its reduced expression.
• TP53TG1 induced the degradation of CIP2A, consequently inhibiting the PI3K/AKT signaling pathway.

Conclusions:

• TP53TG1 functions as a tumor suppressor in gastric cancer.
• The ALKBH5-TP53TG1-CIP2A axis regulates GC progression via the PI3K/AKT pathway.
• TP53TG1 represents a promising therapeutic target for gastric cancer treatment.